[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-cancer-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-cancer-lung-cancer":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100416347",false,"NCT04701476","TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab","Inclusion Criteria:\n\n* Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations\n* mCRC progressed on at least two lines of standard chemotherapy; or\n* NSCLC progressed on chemotherapy and an immune checkpoint inhibitor\n* Measurable disease\n* ECOG 0-1\n* At least 4 weeks from prior chemotherapy and free from chemo-related toxicity\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior organ transplantation\n* Liver metastasis more than 50%\n* Oxygen saturation less than 92% in room air\n* Prior autoimmune disorder\n* CNS metastasis\n* Major GI bleeding in the last 2 months","ALL","18 Years",{"count":18,"type":19},110,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.",[25],"Colorectal Cancer; Lung Cancer",[27,28,29,30,31],"colorectal cancer","NSCLC","pembrolizumab","tirapazamine","Liver metastasis","RECRUITING","2026-04-15",{"date":35,"type":36},"2026-04-16","ACTUAL",{"date":38,"type":36},"2021-05-20",{"date":40,"type":19},"2027-09-30",{"name":42,"class":43},"Teclison Ltd.","INDUSTRY",3,""]